Dyne Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$468.2 | -$343.9 | -$242.2 | -$171.0 | -$150.0 |
| Net income | -$446.2 | -$317.4 | -$235.9 | -$168.1 | -$149.3 |
| Balance Sheet | |||||
| Total debt | $150.0 | — | — | — | — |
| Cash Flow Statement | |||||
| Free cash flow | -$405.1 | -$294.7 | -$188.9 | -$156.7 | -$123.2 |
Shares outstanding 186.7M · Free float 95.1%
Annual filing data through FY ended December 31, 2025; float as of October 5, 2026.